Hinge Health (HNGE) – Research Analysts’ Recent Ratings Updates

Hinge Health (NYSE: HNGE) has recently received a number of price target changes and ratings updates:

• 8/5/2026 – Hinge Health had its “outperform” rating reaffirmed by Evercore Inc. They now have a $105.00 price target on the stock.
• 8/5/2026 – Hinge Health had its price target raised by Royal Bank Of Canada from $75.00 to $110.00. They now have an “outperform” rating on the stock.
• 8/5/2026 – Hinge Health was given a new $105.00 price target by Canaccord Genuity Group Inc..
• 8/5/2026 – Hinge Health was given a new $96.00 price target by Stifel Nicolaus.
• 8/5/2026 – Hinge Health had its price target raised by Barclays PLC from $97.00 to $100.00. They now have an “overweight” rating on the stock.
• 8/5/2026 – Hinge Health had its price target raised by Wells Fargo & Company from $90.00 to $103.00. They now have an “overweight” rating on the stock.
• 8/5/2026 – Hinge Health had its price target raised by Citizens Jmp from $96.00 to $107.00. They now have a “market outperform” rating on the stock.
• 8/5/2026 – Hinge Health had its price target raised by Needham & Company LLC from $76.00 to $97.00. They now have a “buy” rating on the stock.
• 8/3/2026 – Hinge Health had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/27/2026 – Hinge Health had its price target raised by Stifel Nicolaus from $79.00 to $90.00. They now have a “buy” rating on the stock.
• 7/27/2026 – Hinge Health had its “outperform” rating reaffirmed by Citigroup Inc..
• 7/27/2026 – Hinge Health had its price target raised by Citizens Jmp from $80.00 to $96.00. They now have a “market outperform” rating on the stock.
• 7/21/2026 – Hinge Health had its price target raised by Canaccord Genuity Group Inc. from $76.00 to $100.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Hinge Health had its price target raised by Barclays PLC from $70.00 to $97.00. They now have an “overweight” rating on the stock.
• 7/13/2026 – Hinge Health had its price target raised by KeyCorp from $90.00 to $125.00. They now have an “overweight” rating on the stock.
• 7/13/2026 – Hinge Health had its price target raised by Morgan Stanley from $72.00 to $108.00. They now have an “overweight” rating on the stock.
• 6/23/2026 – Hinge Health had its price target raised by Wells Fargo & Company from $80.00 to $90.00. They now have an “overweight” rating on the stock.
• 6/17/2026 – Hinge Health had its price target raised by Robert W. Baird from $55.00 to $65.00. They now have a “neutral” rating on the stock.
• 6/15/2026 – Hinge Health had its price target raised by Raymond James Financial, Inc. from $70.00 to $80.00. They now have an “outperform” rating on the stock.
• 6/15/2026 – Hinge Health had its price target raised by Canaccord Genuity Group Inc. from $65.00 to $76.00. They now have a “buy” rating on the stock.
• 6/12/2026 – Hinge Health had its price target raised by KeyCorp from $75.00 to $90.00. They now have an “overweight” rating on the stock.
• 6/11/2026 – Hinge Health had its price target raised by Barclays PLC from $62.00 to $70.00. They now have an “overweight” rating on the stock.
• 6/11/2026 – Hinge Health had its price target raised by Royal Bank Of Canada from $65.00 to $75.00. They now have an “outperform” rating on the stock.
• 6/11/2026 – Hinge Health had its price target raised by Truist Financial Corporation from $79.00 to $85.00. They now have a “buy” rating on the stock.
• 6/11/2026 – Hinge Health had its price target raised by Needham & Company LLC from $63.00 to $76.00. They now have a “buy” rating on the stock.
• 6/10/2026 – Hinge Health had its “overweight” rating reaffirmed by Piper Sandler.
• 6/10/2026 – Hinge Health was given a new $79.00 price target by Stifel Nicolaus.

Insider Transactions at Hinge Health

In other Hinge Health news, Chairman Gabriel M.I. Mecklenburg sold 83,334 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $60.22, for a total transaction of $5,018,373.48. Following the transaction, the chairman directly owned 83,334 shares of the company’s stock, valued at approximately $5,018,373.48. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Insight Holdings Group, Llc sold 1,466,667 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $82.83, for a total value of $121,484,027.61. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 3,721,100 shares of company stock worth $288,210,699. 18.92% of the stock is owned by company insiders.

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.